Discontinued — last reported Q4 '24
Edwards Lifesciences Derivative Liability, Current decreased by 70.0% to $7.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.6%, from $10.50M to $7.60M. Over 5 years (FY 2020 to FY 2025), Derivative Liability, Current shows a downward trend with a -8.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates potential near-term cash outflows to settle hedging obligations.
This represents the fair value of derivative financial instruments that are expected to be settled within the next twelv...
Monitored by investors to assess short-term cash flow volatility in energy companies.
current_liabilities_derivative_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.90M | $3.50M | $3.90M | $3.80M | $2.00M | $4.40M | $20.70M | $23.40M | $17.80M | $6.70M | $15.20M | $4.90M | $4.70M | $24.30M | $8.30M | $10.50M | $54.20M | $34.50M | $25.30M | $7.60M |
| QoQ Change | — | -55.7% | +11.4% | -2.6% | -47.4% | +120.0% | +370.5% | +13.0% | -23.9% | -62.4% | +126.9% | -67.8% | -4.1% | +417.0% | -65.8% | +26.5% | +416.2% | -36.3% | -26.7% | -70.0% |
| YoY Change | — | — | — | — | -74.7% | +25.7% | +430.8% | +515.8% | +790.0% | +52.3% | -26.6% | -79.1% | -73.6% | +262.7% | -45.4% | +114.3% | >999% | +42.0% | +204.8% | -27.6% |